Ischemic heart disease
Conditions
Interventions
The patients received daily 1800mg EPA and ordinary statin therapy for 2 years.
The patients received daily 10mg ezetimibe and ordinary statin therapy for 2 years.
The patients received ordinary stati
Sponsors
Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who underwent percutaneous coronary intervention (PCI) for ischemic heart diseases and having LDL levels > 100 mg/dL without lipid-lowering therapy. Of them, the patients who had vulnerable plaque were enrolled in this study.
Exclusion criteria
Exclusion criteria: Patients were excluded from the study if they (1) were already using statins or other lipid-lowering therapies, (2) had known hypersensitivity to statins or contrast, (3) had end-stage renal failure (serum creatinine [Cre] ≥ 2.0 mg/dL), (4) demonstrated hemodynamic and respiratory instability (e.g., cardiogenic shock, severe congestive heart failure), or (5) had no consent to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibrous-cap thickness and lipid burden in vulnerable plaque assessed by OCT | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of death, revascularization, myocardial infarction for 2 years | — |
Countries
Japan
Contacts
Public ContactRyo Nishio
Kobe University Graduate School of Medicine Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine
Outcome results
None listed